Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of JD123 CAR-NK in R/R CD123+ AML
NCT06201247Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JD123 in acute myeloid leukemia (AML), sponsored by Peking University People's Hospital. Primary endpoint: Dose-Limiting Toxicities at 1 month. Started Dec 2023; status: recruiting.
02
Drugs
JD123
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06201247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06201247.